Is atezolizumab plus bevacizumab with chemotherapy effective for non-small cell lung cancer with EGFR- or ALK-alteration?
@article{ACTR9451,
author = {Yu Saida and Satoshi Watanabe and Toshiaki Kikuchi},
title = {Is atezolizumab plus bevacizumab with chemotherapy effective for non-small cell lung cancer with EGFR- or ALK-alteration?},
journal = {AME Clinical Trials Review},
volume = {2},
number = {0},
year = {2024},
keywords = {},
abstract = {},
issn = {3005-6152}, url = {https://actr.amegroups.org/article/view/9451}
}